International Journal of Molecular Sciences Cancer's Achilles' Heel: Apoptosis and Necroptosis to the Rescue
暂无分享,去创建一个
[1] Ping Wang,et al. Necroptosis in tumorigenesis, activation of anti-tumor immunity, and cancer therapy , 2016, Oncotarget.
[2] G. Ichim,et al. A fate worse than death: apoptosis as an oncogenic process , 2016, Nature Reviews Cancer.
[3] M. MacFarlane,et al. Targeting cell death signalling in cancer: minimising ‘Collateral damage' , 2016, British Journal of Cancer.
[4] Jian Yu,et al. Necroptosis: an alternative cell death program defending against cancer. , 2016, Biochimica et biophysica acta.
[5] Mariko Sasaki,et al. Targeting p300 Addiction in CBP-Deficient Cancers Causes Synthetic Lethality by Apoptotic Cell Death due to Abrogation of MYC Expression. , 2016, Cancer discovery.
[6] Z. Yang,et al. Cancer therapy in the necroptosis era , 2016, Cell Death and Differentiation.
[7] Li Jin,et al. CaMKII is a RIP3 substrate mediating ischemia- and oxidative stress–induced myocardial necroptosis , 2016, Nature Medicine.
[8] T. Bivona,et al. The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors , 2016, Molecular & cellular oncology.
[9] Amy McKee,et al. Successes and Challenges of PARP Inhibitors in Cancer Therapy , 2015, Front. Oncol..
[10] Liang Zhao,et al. FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy , 2015, Clinical Cancer Research.
[11] I. Rivens,et al. A study of thermal dose-induced autophagy, apoptosis and necroptosis in colon cancer cells , 2015, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.
[12] A. Trumpp,et al. A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer , 2015, Cell.
[13] Francesca M Buffa,et al. Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. , 2015, The Journal of clinical investigation.
[14] R. Bohle,et al. RIPK3 expression in cervical cancer cells is required for PolyIC-induced necroptosis, IL-1α release, and efficient paracrine dendritic cell activation , 2015, Oncotarget.
[15] M. Erlacher,et al. How cell death shapes cancer , 2015, Cell Death and Disease.
[16] R. Majeti,et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia , 2015, Nature Medicine.
[17] P. Vandenabeele,et al. Necroptosis and its role in inflammation , 2015, Nature.
[18] T. Vanden Berghe,et al. Necroptosis, in vivo detection in experimental disease models. , 2014, Seminars in cell & developmental biology.
[19] S. Fesik,et al. Drugging the undruggable RAS: Mission Possible? , 2014, Nature Reviews Drug Discovery.
[20] R. Bernards,et al. RAF suppression synergizes with MEK inhibition in KRAS mutant cancer cells. , 2014, Cell reports.
[21] H. Ogiwara,et al. Proposal for a synthetic lethality therapy using the paralog dependence of cancer cells--response. , 2014, Cancer research.
[22] Eytan Ruppin,et al. Predicting Cancer-Specific Vulnerability via Data-Driven Detection of Synthetic Lethality , 2014, Cell.
[23] Sourav Bandyopadhyay,et al. Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer , 2014, Proceedings of the National Academy of Sciences.
[24] P. Vandenabeele,et al. Regulated necrosis: the expanding network of non-apoptotic cell death pathways , 2014, Nature Reviews Molecular Cell Biology.
[25] Erinna F. Lee,et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53 , 2014, Genes & development.
[26] Ling-gang Wu,et al. Plasma membrane translocation of trimerized MLKL protein is required for TNF-induced necroptosis , 2013, Nature Cell Biology.
[27] P. Johnston,et al. Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.
[28] K. Vousden,et al. Interaction of p53 with the CCT Complex Promotes Protein Folding and Wild-Type p53 Activity , 2013, Molecular cell.
[29] K. Shokat,et al. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers , 2013, Proceedings of the National Academy of Sciences.
[30] A. Safa. Roles of c-FLIP in Apoptosis, Necroptosis, and Autophagy , 2013, Journal of carcinogenesis & mutagenesis.
[31] David R McIlwain,et al. Caspase functions in cell death and disease. , 2013, Cold Spring Harbor perspectives in biology.
[32] Travis J Cohoon,et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. , 2013, Cancer cell.
[33] T. Akihisa,et al. Kuguaglycoside C, a constituent of Momordica charantia, induces caspase‐independent cell death of neuroblastoma cells , 2012, Cancer science.
[34] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[35] M. MacFarlane,et al. The 'complexities' of life and death: death receptor signalling platforms. , 2012, Experimental cell research.
[36] Sven Diederichs,et al. The hallmarks of cancer , 2012, RNA biology.
[37] R. Medema,et al. Checkpoint control and cancer , 2012, Oncogene.
[38] G. McArthur,et al. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells , 2012, Oncogene.
[39] Mari Mino-Kenudson,et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. , 2012, Cancer discovery.
[40] R. Bernards,et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.
[41] M. Barbacid,et al. Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors , 2011, Nature Structural &Molecular Biology.
[42] D. Green,et al. RIPK-dependent necrosis and its regulation by caspases: a mystery in five acts. , 2011, Molecular cell.
[43] R. Young,et al. BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.
[44] Xiangwei Wu,et al. Lung-Cancer Chemoprevention by Induction of Synthetic Lethality in Mutant KRAS Premalignant Cells In Vitro and In Vivo , 2011, Cancer Prevention Research.
[45] I. Endo,et al. The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells , 2011, Leukemia.
[46] S. Susin,et al. AIF‐mediated caspase‐independent necroptosis: A new chance for targeted therapeutics , 2011, IUBMB life.
[47] M. Peter,et al. Programmed cell death: Apoptosis meets necrosis , 2011, Nature.
[48] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[49] R. Hakem,et al. RIP3 mediates the embryonic lethality of caspase-8-deficient mice , 2011, Nature.
[50] Guy S. Salvesen,et al. Catalytic activity of the caspase-8-FLIPL complex inhibits RIPK3-dependent necrosis , 2011, Nature.
[51] D. Green,et al. Cell survival in tough times: The mitochondrial recovery plan , 2010, Cell cycle.
[52] P. Vandenabeele,et al. Molecular mechanisms of necroptosis: an ordered cellular explosion , 2010, Nature Reviews Molecular Cell Biology.
[53] K. Flaherty,et al. Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.
[54] Hong Liu,et al. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase , 2010, Proceedings of the National Academy of Sciences.
[55] Q. She,et al. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. , 2010, Cancer cell.
[56] D. Livingston,et al. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. , 2010, Carcinogenesis.
[57] T. Vanden Berghe,et al. The Role of the Kinases RIP1 and RIP3 in TNF-Induced Necrosis , 2010, Science Signaling.
[58] D. Silver,et al. Synthetic lethality--a new direction in cancer-drug development. , 2009, The New England journal of medicine.
[59] Christoph Borner,et al. XIAP discriminates between type I and type II FAS-induced apoptosis , 2009, Nature.
[60] P. Vandenabeele,et al. RIP Kinases at the Crossroads of Cell Death and Survival , 2009, Cell.
[61] F. Chan,et al. Phosphorylation-Driven Assembly of the RIP1-RIP3 Complex Regulates Programmed Necrosis and Virus-Induced Inflammation , 2009, Cell.
[62] G. Salvesen,et al. Human Caspases: Activation, Specificity, and Regulation* , 2009, The Journal of Biological Chemistry.
[63] P. Sorger,et al. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.
[64] K. Kinzler,et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53 , 2009, Proceedings of the National Academy of Sciences.
[65] L. Galluzzi,et al. Necroptosis: A Specialized Pathway of Programmed Necrosis , 2008, Cell.
[66] T. Kuwana,et al. Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins , 2008, Proceedings of the National Academy of Sciences.
[67] Lisa S. Chen,et al. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells. , 2008, Blood.
[68] John Calvin Reed,et al. Bcl-2 family proteins and cancer , 2008, Oncogene.
[69] Elizabeth Iorns,et al. A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor , 2008, The EMBO journal.
[70] Alexei Degterev,et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. , 2008, Nature chemical biology.
[71] D. Green,et al. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? , 2008, Trends in cell biology.
[72] A. Letai,et al. Diagnosing and exploiting cancer's addiction to blocks in apoptosis , 2008, Nature Reviews Cancer.
[73] M. Ranson,et al. X-linked inhibitor of apoptosis protein as a therapeutic target , 2007, Expert opinion on therapeutic targets.
[74] A. Tward,et al. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC , 2007, Nature Medicine.
[75] S. Elmore. Apoptosis: A Review of Programmed Cell Death , 2007, Toxicologic pathology.
[76] Michael Peyton,et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells , 2007, Nature.
[77] Michael B Yaffe,et al. p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. , 2007, Cancer cell.
[78] T. Jacks,et al. Restoration of p53 function leads to tumour regression in vivo , 2007, Nature.
[79] Carlos Cordon-Cardo,et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.
[80] W. Kaelin. The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.
[81] Alexei Degterev,et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury , 2005, Nature chemical biology.
[82] Xiao-Ming Yin,et al. Deletion of Bid impedes cell proliferation and hepatic carcinogenesis. , 2005, The American journal of pathology.
[83] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[84] Thomas Helleday,et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.
[85] J. E. Duque-Parra. Note on the origin and history of the term "apoptosis". , 2005, Anatomical record. Part B, New anatomist.
[86] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[87] Marc Nasoff,et al. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. , 2004, Cancer cell.
[88] R. Wooster,et al. Breast and ovarian cancer. , 2003, The New England journal of medicine.
[89] Jiri Bartek,et al. Chk1 and Chk2 kinases in checkpoint control and cancer. , 2003, Cancer cell.
[90] Y. Shiloh. ATM and related protein kinases: safeguarding genome integrity , 2003, Nature Reviews Cancer.
[91] Xin Lu,et al. Live or let die: the cell's response to p53 , 2002, Nature Reviews Cancer.
[92] R. Pierce,et al. Bcl-2 expression inhibits liver carcinogenesis and delays the development of proliferating foci. , 2002, The American journal of pathology.
[93] G. Cohen,et al. The Apaf-1 apoptosome: a large caspase-activating complex. , 2002, Biochimie.
[94] Ashok R Venkitaraman,et al. Cancer Susceptibility and the Functions of BRCA1 and BRCA2 , 2002, Cell.
[95] Jun Yu Li,et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. , 2001, Cancer research.
[96] T. Mak,et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death , 2001, Nature.
[97] Brian Seed,et al. Fas triggers an alternative, caspase-8–independent cell death pathway using the kinase RIP as effector molecule , 2000, Nature Immunology.
[98] S. Elledge,et al. The DNA damage response: putting checkpoints in perspective , 2000, Nature.
[99] John Savill,et al. Corpse clearance defines the meaning of cell death , 2000, Nature.
[100] G. Häcker. The morphology of apoptosis , 2000, Cell and Tissue Research.
[101] Ruedi Aebersold,et al. Molecular characterization of mitochondrial apoptosis-inducing factor , 1999, Nature.
[102] Y. Lazebnik,et al. Caspases: enemies within. , 1998, Science.
[103] Xiaodong Wang,et al. Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.
[104] S. Korsmeyer,et al. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. , 1998, Blood.
[105] M. Peter,et al. Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.
[106] R E Burke,et al. Apoptosis in neurodegenerative disorders. , 1997, Current opinion in neurology.
[107] J C Reed,et al. Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.
[108] C. Kitanaka,et al. Apoptosis in cancer. , 1996, Human cell.
[109] E. Sausville,et al. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. , 1996, Journal of the National Cancer Institute.
[110] M. Raff,et al. The Role of Apoptosis in Development, Tissue Homeostasis and Malignancy , 1995, Springer Netherlands.
[111] Y. Tsujimoto,et al. Involvement of the bcl-2 gene in human follicular lymphoma. , 1985, Science.
[112] P. Nowell,et al. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(11 ; 14) chromosome translocation , 1985, Nature.
[113] S. Kaye,et al. PARP inhibitors: the race is on. , 2016, British journal of cancer.
[114] D. Green,et al. Molecular Cell Biology of Apoptosis and Necroptosis in Cancer. , 2016, Advances in experimental medicine and biology.
[115] Lucio Crinò,et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.
[116] R. Mohammad,et al. Small-molecule inhibitors of Bcl-2 family proteins as therapeutic agents in cancer. , 2008, Recent patents on anti-cancer drug discovery.
[117] S. Mariathasan,et al. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation , 2007, Nature Reviews Immunology.